Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03109873 · ClinicalTrials.gov registry record · Early Phase 1
Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer
A Early Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
NCT03109873: Completed Early Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
NCT03109873 is a Early Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 9 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03109873, a Early Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This pilot clinical trial studies how well metformin hydrochloride works in affecting cytokines and exosomes in patients with head and neck cancer. Metformin hydrochloride may reduce the metabolic activity of cancer cells and of surrounding supportive tissues.
Primary Outcome
Mixed effects linear regression will be used to model longitudinal measurements of each cytokine.
Interventions
- OTHER Placebo
- RADIATION External Beam Radiation Therapy
- DRUG Metformin Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-01-05 |
| Est. Completion | 2020-07-31 |
| Phase | Early Phase 1 |
What the finished NCT03109873 record still lists
NCT03109873 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03109873 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03109873 about?
NCT03109873 is a clinical study titled "Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer". This pilot clinical trial studies how well metformin hydrochloride works in affecting cytokines and exosomes in patients with head and neck cancer. Metformin hydrochloride may reduce the metabolic activity of cancer cells and of surrounding supportive tissues.
What is the current status of trial NCT03109873?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2017-01-05. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT03109873?
The interventions under investigation include: Placebo (OTHER), External Beam Radiation Therapy (RADIATION), Metformin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03109873?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03109873's enrollment target sits among peer trials
9 1746th of 2000 higher than 219 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI